{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Open-Label Treatment Period 1', 'Follow-Up Period', 'Follow-Up Contact 3', '(24 Weeks)', '2', '(24 weeks)', '(48 Weeks)', '11/', 'FU3/', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'PWEO', 'FU1', 'FU2', 'FU4', 'FU5', 'FU4', 'FU5', 'PWEOS', 'T4', 'Week (W)/', 'Day 16', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W48/', 'W72/', 'W72/', 'W96/', 'Month (M)', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M12', 'M18', 'M18', 'M24', 'Visit Window ( days)', '(+14)', '(+1)', '(+3)', '(+1)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', '(+14)', '(+14)', 'Proptosis', 'Subject response in', 'Proptosis Non-responder', 'Proptosis Non-responder or Relapse', 'Relapse Only', 'Study HZNP-TEP-301', 'Non-responder', 'Only', 'Only', 'Glucose 19', 'X9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'HbAlc', 'X9', 'X', 'X', 'Urinalysis', 'X9', 'X', 'X', 'X', 'X', 'ADA/NAb samples 20', 'X9', 'X2', 'X', 'X', 'AE, SAE', 'X9', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X9', 'X', 'X', 'X', 'GO-QoL Questionnaire', 'X9', 'X', 'PK samples 23', 'x21', 'Contact (phone/email) to', 'assess additional TED', 'treatment 24', 'ADA=anti-drug antibody; AE=adverse event; CAS=Clinical Activity Score; ECG=electrocardiogram; EOT-EndofTreatment: End of Study; triiodothyronine;', \"FT4=free thyroxine; FU=Follow-Up; GO-QoL=Graves' Ophthalmopathy Quality of Life Questionnaire; HbAlc=glycated hemoglobin; M=month; NAb=neutralizing antibody;\", 'PK=pharmacokinetic; PW=premature withdrawal; SAE=serious adverse event; TED=thyroid eye disease; TSH=thyroid stimulating hormone;', 'W=week.', 'Footnotes:', '1.', 'Open-label Treatment Period. Subjects with TED who are proptosis non-responders at Week 24 of HZNP-TEP-301 or were proptosis responders at Week 24 but who meet', 'criteria for re-treatment due to relapse during the Follow-Up Period in HZNP-TEP-301 are eligible to enroll and receive upto 8 infusions of teprotumumab (10 mg/kg for the', 'first infusion titrated to 20 mg/kg for the remaining infusions) in an open-label fashion.', '2.', 'The number of infusions and length of participation in the open label Treatment Period will be determined by the Investigator elinical judgment (but not to exceed 8', 'infusions).', '23. Proptosis non-responders from Study HZNP-TEP-301 will participate in a 6-month Follow-Up Period; subjects who relapsed during the Follow-Up Period of HZNP-TEP-301', 'will not participate.', '3. Proptosis non-responders from Study HZNP-TEP-301 who complete the Month 12 Visit and subjects who relapsed during the Follow-Up Period of HZNP-TEP-301', 'and complete the Week 24 Visit will be contacted via phone or email bv research staff to enquire if any treatment for TED has been received since last study', 'contact.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 12 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '4.', 'Once the Investigator deems study drug dosing to be complete, orilf subjects wish to discontinue study drug during the open-label Treatment Period, subjects will return for a', 'clinic visit 3 weeks after the final dose and undergo the Week 24 End of Treatment (EOT) assessments, except for PK and ADA evaluations. Subjects who were proptosis', 'non-responders at Week 24 of HZNP-TEP-301 will be encouraged to continue study participation in the Follow-Up Period.', '5.', 'If a subject wishes to prematurely discontinue from the study during the Follow-Up Period, he/she will return for a clinic visit and undergo the Month 12 ind of Study', '[EOS])-assessments prior to discharge.', '6. On Day 1 (Baseline), subjects will receive the first dose of study drug; however, Baseline assessments will be performed prior to dosing.', '7.', 'Day 1 will occur within 14 days after the final visit of Study HZNP-TEP-301 (Week 24 for proptosis non-responders and up to Week 72 for subjects who relapse).', '8.', 'Dosing will be adjusted if there is a change in weight during the Treatment Period. The weight obtained at Week 12 can be used in dose calculations beginning at', 'Week 12 or Week 15.', '9.', 'If Day 1 of the extension study occurs on the same day as the final visit of HZNP-TEP-301 (Week 24 [or PW1] for proptosis non-responders and Week 72 [or PW2] for', 'subjects who relapse), assessments do not need to be repeated, and the final assessments from the lead-in study will serve as the Baseline assessments for the extension study.', '10. Subjects will receive teprotumumab 10 mg/kg on Day 1 followed by 20 mg/kg q3W for the 7 remaining infusions.', '11. Phone (or email) contact by research staff focusing on safety and tolerability aspects will be made the day after infusion for the first and second infusions, and thereafter as', 'deemed appropriate. In addition, subjects who experience an infusion-associated event after any subsequent infusion will also be contacted by phone (or email) by research', 'staff the day after the infusion, and thereafter as deemed appropriate.', '12. Perform urine pregnancy tests prior to dose (as applicable) for female subjects of childbearing potential (including those with an onset of menopause <2 years prior to', 'Baseline of HZNP-TEP-302, non-therapy-induced amenorrhea for <12 months prior to Baseline of HZNP-TEP-302, or not surgically sterile [absence of ovaries and/or', 'uterus]).', '13. Physical exam will include assessment of presence or absence of pretibial myxedema on Day 1 and Week 24/PWEOT of the Treatment Period and Month 12/PWEOS of the', 'Follow-Up Period. If present, measurements of instep and calf will be taken.', '14. Ophthalmic exam: best corrected visual acuity, pupil exam, color vision assessment, Ishihara color plates (or equivalent) or related red desaturation, intraocular pressure, and', 'slit lamp exam. If significant abnormalities are noted compared to previous visits, including a loss of 2 lines or more of vision, development of pupil abnormalities including', 'APD, rise in intraocular pressure, development of corneal infiltrates or other abnormalities not here specified but of concern to the ophthalmologist, further investigations of', 'visual function will be conducted according to the ophthalmologist decision.', '15. Vital signs (heart rate, blood pressure, respiratory rate, temperature) will be measured at all clinic visits. Vital signs will be measured pre- and post-infusion on Day 1 and', 'Week 3, and pre-dose on all other infusion days. Additional vital signs will be monitored if infusion-associated AEs occur (see Section 9.5.4.3 for details).', '16. Non-diabetic subjects should be fasting at Weeks 1 and 4 only. Diabetic subjects should be fasting at each visit blood glucose is evaluated.', '17. ALT/AST must be <3 x the upper limit of normal (ULN) and serum creatinine must be <1.5 x the ULN (according to age) at the most recent clinic visit to be eligible for', 'enrollment.', '18. Subjects must be euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3]', 'levels < 50% above or below the normal limits) at the most recent clinic visit. Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to', 'maintain the euthyroid state for the full duration of the clinical trial.', '19. HbAlc must be < 9.0% at the most recent clinic visit. If the HbAlc is elevated and considered clinically significant at any time point after Baseline, it will be repeated', 'approximately every 45 days until it returns to normal or the baseline value.', '20. If a sample is positive in the ADA test, after confirmatory and reactive titer testing, the sample will then be tested for NAb. If the subject tests positive for NAb, he/she will be', \"followed until levels either revert to Baseline or the subject's value decreases or remains stable. Any subject with a positive NAb test at Week 48 (or PW) during the\", \"Follow-Up Period will continue to be followed until the subject's value decreases or remains stable.\", '21. Not collected for subjects who prematurely discontinue from the open-label Treatment Period.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 13 of 118']\n\n###\n\n", "completion": "END"}